The future of systemic therapy for cutaneous squamous cell carcinoma (CSCC) is rapidly evolving, with research focused on ...

Neoadjuvant immunotherapy is emerging as a valuable option for patients with complex or borderline resectable cutaneous squamous cell carcinoma (CSCC). Administered before surgery, PD-1 inhibitors ...

SAN FRANCISCO -- Neoadjuvant chemoradiotherapy with or without the investigational PD-1 inhibitor sintilimab significantly increased pathological complete response (pCR) rates compared with ...

The efficacy of immunotherapy against triple-negative breast cancer (TNBC) heavily relies on intratumoral infiltration of cytotoxic T lymphocytes (CTLs). Although neoadjuvant chemotherapy together ...

Neoadjuvant immunotherapy is expanding treatment options in CSCC by shrinking complex tumors, improving surgical outcomes, ...

Please provide your email address to receive an email when new articles are posted on . Neoadjuvant pembrolizumab induced pathologic complete response in 71% of patients with desmoplastic melanoma.

A recent study published in JAMA Oncology presents promising new data on a treatment regimen beneficial to patients with a subset of head and neck cancer known as oropharyngeal cancer. A rare ...

Please provide your email address to receive an email when new articles are posted on . The addition of nivolumab to neoadjuvant chemotherapy significantly increased pathologic complete response among ...

US Food and Drug Administration Approval Summary: Nivolumab Plus Platinum-Doublet Chemotherapy for the Neoadjuvant Treatment of Patients With Resectable Non–Small-Cell Lung Cancer The following ...

The results of the phase 3 ATOMIC trial fired another volley in the ongoing debate over adjuvant vs neoadjuvant immunotherapy for patients with locally advanced colon cancer. But experts are divided ...

In a national cohort study of patients with resectable head and neck squamous cell carcinoma (HNSCC), the number receiving neoadjuvant immunotherapy began to rise markedly in 2013, while use of ...

Interim results from the phase 2 NESCIO trial suggest combination neoadjuvant immunotherapy has efficacy in locally advanced clear cell renal cell carcinoma. Neoadjuvant combinations of ipilimumab or ...